224 related articles for article (PubMed ID: 29067902)
21. Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price.
Amick AK; Eskibozkurt GE; Hosek SG; Flanagan CF; Landovitz RJ; Jin EY; Wilson CM; Freedberg KA; Weinstein MC; Kazemian P; Paltiel AD; Ciaranello AL; Neilan AM
Clin Infect Dis; 2024 Feb; 78(2):402-410. PubMed ID: 37823865
[TBL] [Abstract][Full Text] [Related]
22. Evaluating the impact of prioritization of antiretroviral pre-exposure prophylaxis in New York.
Kessler J; Myers JE; Nucifora KA; Mensah N; Toohey C; Khademi A; Cutler B; Braithwaite S
AIDS; 2014 Nov; 28(18):2683-91. PubMed ID: 25493594
[TBL] [Abstract][Full Text] [Related]
23. Preparing for PrEP: estimating the size of the population eligible for HIV pre-exposure prophylaxis among men who have sex with men in England.
Mitchell HD; Desai S; Mohammed H; Ong KJ; Furegato M; Hall V; Desai M; Saunders JM; Hughes G; Field N; Gill ON
Sex Transm Infect; 2019 Nov; 95(7):484-487. PubMed ID: 31010953
[TBL] [Abstract][Full Text] [Related]
24. Can we afford to offer pre-exposure prophylaxis to MSM in Catalonia? Cost-effectiveness analysis and budget impact assessment.
Reyes-Urueña J; Campbell C; Diez E; Ortún V; Casabona J
AIDS Care; 2018 Jun; 30(6):784-792. PubMed ID: 29262694
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of HIV pre-exposure prophylaxis in Japan.
Mizushima D; Nagai Y; Mezzio D; Harada K; Piao Y; Barnieh L; El Moustaid F; Cawson M; Taniguchi T
J Med Econ; 2023; 26(1):886-893. PubMed ID: 37421417
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness and impact of pre-exposure prophylaxis to prevent HIV among men who have sex with men in Asia: A modelling study.
Ten Brink DC; Martin-Hughes R; Minnery ME; Osborne AJ; Schmidt HA; Dalal S; Green KE; Ramaurtarsing R; Wilson DP; Kelly SL
PLoS One; 2022; 17(5):e0268240. PubMed ID: 35617169
[TBL] [Abstract][Full Text] [Related]
27. The effect of combination prevention strategies on HIV incidence among gay and bisexual men who have sex with men in the UK: a model-based analysis.
Cambiano V; Miners A; Lampe FC; McCormack S; Gill ON; Hart G; Fenton KA; Cairns G; Thompson M; Delpech V; Rodger AJ; Phillips AN
Lancet HIV; 2023 Nov; 10(11):e713-e722. PubMed ID: 37923485
[TBL] [Abstract][Full Text] [Related]
28. The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India.
Kazemian P; Costantini S; Kumarasamy N; Paltiel AD; Mayer KH; Chandhiok N; Walensky RP; Freedberg KA
Clin Infect Dis; 2020 Feb; 70(4):633-642. PubMed ID: 30921454
[TBL] [Abstract][Full Text] [Related]
29. Gonorrhoea and chlamydia diagnosis as an entry point for HIV pre-exposure prophylaxis: a modelling study.
Kasaie P; Schumacher CM; Jennings JM; Berry SA; Tuddenham SA; Shah MS; Rosenberg ES; Hoover KW; Gift TL; Chesson H; German D; Dowdy DW
BMJ Open; 2019 Mar; 9(3):e023453. PubMed ID: 30837248
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda.
Ying R; Sharma M; Heffron R; Celum CL; Baeten JM; Katabira E; Bulya N; Barnabas RV
J Int AIDS Soc; 2015; 18(4 Suppl 3):20013. PubMed ID: 26198348
[TBL] [Abstract][Full Text] [Related]
31. Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries.
Pretorius C; Schnure M; Dent J; Glaubius R; Mahiane G; Hamilton M; Reidy M; Matse S; Njeuhmeli E; Castor D; Kripke K
J Int AIDS Soc; 2020 Feb; 23(2):e25451. PubMed ID: 32112512
[TBL] [Abstract][Full Text] [Related]
32. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.
Long EF; Stavert RR
J Gen Intern Med; 2013 Oct; 28(10):1294-301. PubMed ID: 23588668
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study.
Phillips AN; Bershteyn A; Revill P; Bansi-Matharu L; Kripke K; Boily MC; Martin-Hughes R; Johnson LF; Mukandavire Z; Jamieson L; Meyer-Rath G; Hallett TB; Ten Brink D; Kelly SL; Nichols BE; Bendavid E; Mudimu E; Taramusi I; Smith J; Dalal S; Baggaley R; Crowley S; Terris-Prestholt F; Godfrey-Faussett P; Mukui I; Jahn A; Case KK; Havlir D; Petersen M; Kamya M; Koss CA; Balzer LB; Apollo T; Chidarikire T; Mellors JW; Parikh UM; Godfrey C; Cambiano V;
Lancet HIV; 2022 May; 9(5):e353-e362. PubMed ID: 35489378
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.
Glaubius RL; Hood G; Penrose KJ; Parikh UM; Mellors JW; Bendavid E; Abbas UL
Clin Infect Dis; 2016 Aug; 63(4):539-47. PubMed ID: 27193745
[TBL] [Abstract][Full Text] [Related]
35. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.
Smith J; Bansi-Matharu L; Cambiano V; Dimitrov D; Bershteyn A; van de Vijver D; Kripke K; Revill P; Boily MC; Meyer-Rath G; Taramusi I; Lundgren JD; van Oosterhout JJ; Kuritzkes D; Schaefer R; Siedner MJ; Schapiro J; Delany-Moretlwe S; Landovitz RJ; Flexner C; Jordan M; Venter F; Radebe M; Ripin D; Jenkins S; Resar D; Amole C; Shahmanesh M; Gupta RK; Raizes E; Johnson C; Inzaule S; Shafer R; Warren M; Stansfield S; Paredes R; Phillips AN;
Lancet HIV; 2023 Apr; 10(4):e254-e265. PubMed ID: 36642087
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness Analysis of a National Pre-Exposure Prophylaxis (PrEP) Program in Ireland.
O Murchu E; Teljeur C; Hayes C; Harrington P; Moran P; Ryan M
Value Health; 2021 Jul; 24(7):948-956. PubMed ID: 34243838
[TBL] [Abstract][Full Text] [Related]
37. The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study.
Gomez GB; Borquez A; Caceres CF; Segura ER; Grant RM; Garnett GP; Hallett TB
PLoS Med; 2012; 9(10):e1001323. PubMed ID: 23055836
[TBL] [Abstract][Full Text] [Related]
38. Use of HIV pre-exposure prophylaxis among men who have sex with men in England: data from the AURAH2 prospective study.
Hanum N; Cambiano V; Sewell J; Phillips AN; Rodger AJ; Speakman A; Nwokolo N; Asboe D; Gilson R; Clarke A; Miltz AR; Collins S; Lampe FC;
Lancet Public Health; 2020 Sep; 5(9):e501-e511. PubMed ID: 32888443
[TBL] [Abstract][Full Text] [Related]
39. Piloting a partially self-financed mode of human immunodeficiency virus pre-exposure prophylaxis delivery for men who have sex with men in Hong Kong.
Lee SS; Kwan TH; Wong NS; Lee KCK; Chan DPC; Lam TTN; Lui GCY
Hong Kong Med J; 2019 Oct; 25(5):382-391. PubMed ID: 31619578
[TBL] [Abstract][Full Text] [Related]
40. Pre-exposure prophylaxis (PrEP) for MSM in low HIV incidence places: should high risk individuals be targeted?
Wong NS; Kwan TH; Tsang OTY; Lee MP; Yam WC; Lam W; Leung WS; Chan JMC; Ho KM; Lee SS
Sci Rep; 2018 Aug; 8(1):11641. PubMed ID: 30076362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
